Regional Amyloid Deposition in Amnestic Mild Cognitive Impairment and Alzheimer's Disease Evaluated by [18F]AV-45 Positron Emission Tomography in Chinese Population

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Huang, Kuo Lun ^a   Lin, Kun Ju ^a,b   Hsiao, Ing Tsung ^a,b   Kuo, Hung Chou ^a   Hsu, Wen Chuin ^a   Chuang, Wen Li ^a   Kung, Mei Ping ^a,c   Wey, Shiaw Pyng ^a,b   Hsieh, Chia Ju ^a,b   Wai, Yau Yau ^a   Yen, Tzu Chen ^a   Huang, Chin Chang ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; FLORBETAPIR F 18;

AGE; AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; AMYLOIDOSIS; ARTICLE; BRAIN MAPPING; CEREBRAL CORTEX TO WHOLE CEREBELLUM STANDARD UPTAKE VALUE RATIO; CHINESE; CLINICAL ARTICLE; COGNITION; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EDUCATIONAL STATUS; FEMALE; FRONTAL GYRUS; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NERVOUS SYSTEM PARAMETERS; NEUROIMAGING; OCCIPITAL GYRUS; PARIETAL GYRUS; POPULATION RESEARCH; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRECUNEUS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TEMPORAL GYRUS; VOLUME OF INTEREST;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMNESIA; AMYLOID; ASIAN CONTINENTAL ANCESTRY GROUP; BRAIN; CEREBRAL CORTEX; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION TOMOGRAPHY;

EID: 84875044896     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058974     Document Type: Article

References (48)

1. Löppönen M, Räihä I, Isoaho R, Vahlberg T, Kivelä SL, (2003) Diagnosing cognitive impairment and dementia in primary health care - a more active approach is needed. Age Ageing 32: 606-612.
2. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, et al. (2011) Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement 7: 280-292.
3. Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, et al. (2001) Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci 69: 1471-1484.
4. Ono M, Cheng Y, Kimura H, Cui M, Kagawa S, et al. (2011) Novel 18F-labeled benzofuran derivatives with improved properties for positron emission tomography (PET) imaging of β-Amyloid plaques in Alzheimer's brains. J Med Chem 54: 2971-2979.
5. Kudo Y, Okamura N, Furumoto S, Tashiro M, Furukawa K, et al. (2007) 2-(2-[2-dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy) benzoxazole: a Novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med 48: 553-561.
6. Seneca N, Cai L, Liow JS, Zoghbi SS, Gladding RL, et al. (2007) Brain and whole-body imaging in nonhuman primates with [11C]MeS-IMPY, a candidate radioligand for β-amyloid plaques. Nucl Med Biol 34: 681-689.
7. Shoghi-Jadid K, Barrio JR, Kepe V, Wu HM, Small GW, et al. (2005) Imaging β-amyloid fibrils in Alzheimer's disease: a critical analysis through simulation of amyloid fibril polymerization. Nucl Med Biol 32: 337-351.
8. Lin KJ, Hsu WC, Hsiao IT, Wey SP, Jin LW, et al. (2010) Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent- a pilot study. Nucl Med Biol 37: 497-508.
9. Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, et al. (2008) Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 7: 129-135.
10. Koole M, Lewis DM, Buckley C, Nelissen N, Vandenbulcke M, et al. (2009) Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. J Nucl Med 50: 818-822.
11. Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, et al. (2010) The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimer's Dement 6: 221-229.
12. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, et al. (2011) Use of Florbetapir-PET for Imaging β-Amyloid Pathology. JAMA 305: 275-283.
13. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, et al. (2001) Current concepts in mild cognitive impairment. Arch Neurol 58: 1985-1992.
14. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, DSM-IV. Washington, DC: American Psychiatric Association.
15. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. (1984) Clinical diagnosis of Alzheimer's disease. Neurology 34: 939.
16. Folstein MF, Folstein SE, McHugh PR, (1975) Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 12: 189-198.
17. Wang PN, Hong CJ, Lin KN, Liu HC, Chen WT, (2011) APOE ∈4 increases the risk of progression from amnestic mild cognitive impairment to Alzheimer's disease among ethnic Chinese in Taiwan. J Neurol Neurosurg Psychiatry 82: 165-169.
18. Yao CH, Lin KJ, Weng CC, Hsiao IT, Ting YS, et al. (2010) GMP-compliant automated synthesis of [(18)F]AV-45 (Florbetapir F 18) for imaging beta-amyloid plaques in human brain. Appl Radiat Isot 68: 2293-2297.
19. Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, et al. (2010) In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (Florbetapir F 18). J Nucl Med 51: 913-920.
20. Hsiao IT, Huang CC, Hsieh CJ, Hsu WC, Wey SP, et al. (2012) Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies. Eur J Nucl Med Mol Imaging 39: 613-620.
21. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, et al. (2002) Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. NeuroImage 15: 273-289.
22. Huang KL, Lin KJ, Ho MY, Chang YJ, Chang CH, et al. (2012) Amyloid deposition after cerebral hypoperfusion: evidenced on [18F]AV-45 positron emission tomography. J Neurol Sci 319: 124-129.
23. Hsieh CJ, Fan L, Lin KJ, Hsiao IT, Huang CC, et al. (2011) Precise F-18 florbetapir (AV-45) PET image spatial normalization using early-phase image template. J Nucl Med 52: 549.
24. Ashburner J, Friston KJ, (2005) Unified segmentation. NeuroImage 26: 839-851.
25. Juh R, Kim J, Moon D, Choe B, Suh T, (2004) Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET. European Journal of Radiology 51: 223-233.
26. Braak H, Braak E, (1997) Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories. Neurobiol Aging 18: 351-357.
27. Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, et al. (2009) Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 73: 754-760.
28. Small GW, (2006) Diagnostic issues in dementia: neuroimaging as a surrogate marker of disease. J Geriatr Psychiatry Neurol 19: 180-185.
29. Herholz K, Ebmeier K, (2011) Clinical amyloid imaging in Alzheimer's disease. The Lancet Neurology 10: 667-670.
30. Hatashita S, Yamasaki H, (2010) Clinically different stages of Alzheimer's disease associated by amyloid deposition with [11C]-PIB PET imaging. J Alzheimers Dis 21: 995-1003.
31. Barthel H, Senda M, Yamane T, Patt M, Sattler B, et al. (2010) Phase 1 trials on florbetaben brain PET in elderly normal controls. J Nucl Med 51: 385.
32. Senda M, Yamane T, Sasaki M, Shimizu K, Barthel H, et al. (2010) Ethnic comparability of safety and pharmacokinetics of florbetaben (BAY 94-9172) in normal Caucasian and Asian subjects. J Nucl Med 51: 1754.
33. Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, et al. (2011) Using positron emission tomography and florbetapir F 18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol 68: 1404-1411.
34. Jobst KA, Barnetson LPD, Shepstone BJ, (1998) Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-Ray CT, and Apo E4 in medial temporal lobe dementias. Int Psychogeriatr 10: 271-302.
35. Ranginwala NA, Hynan LS, Weiner MF, White CLI, (2008) Clinical criteria for the diagnosis of Alzheimer disease: still good after all these years. Am J Geriatr Psychiatry 16: 384-388.
36. LeVine III H, Walker LC, (2010) Molecular polymorphism of Aβ in Alzheimer's disease. Neurobiol Aging 31: 542-548.
37. Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, et al. (2007) PIB is a non-specific imaging marker of amyloid-beta (Aβ) peptide-related cerebral amyloidosis. Brain 130: 2607-2615.
38. Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, et al. (2007) PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 68: 1603-1606.
39. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, et al. (2008) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29: 1456-1465.
40. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, et al. (2007) Imaging beta-amyloid burden in aging and dementia. Neurology 68: 1718-1725.
41. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, et al. (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65: 1509-1517.
42. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, et al. (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31: 1275-1283.
43. Chetelat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, et al. (2010) Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol 67: 317-324.
44. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, et al. (2009) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 132: 1355-1365.
45. Teipel SJ, Sabri O, Grothe M, Barthel H, Prvulovic D, et al. (2013) Perspectives for Multimodal Neurochemical and Imaging Biomarkers in Alzheimer's Disease. J Alzheimers Dis 33: S329-S347.
46. Roe CM, Mintun MA, D'Angelo G, Xiong C, Grant EA, et al. (2008) Alzheimer Disease and Cognitive Reserve: Variation of Education Effect With Carbon 11-Labeled Pittsburgh Compound B Uptake. Arch Neurol 65: 1467-1471.
47. Barthel H, Luthardt J, Becker G, Patt M, Hammerstein E, et al. (2011) Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls. Eur J Nucl Med Mol Imaging 38: 1702-1714.
48. Jack Jr CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, et al. (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. The Lancet Neurology 9: 119-128.